Pulmonx (NASDAQ:LUNG) Insider Sells $14,990.69 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Srikanth Radhakrishnan sold 10,483 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $14,990.69. Following the transaction, the insider owned 170,736 shares of the company’s stock, valued at $244,152.48. This represents a 5.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulmonx Stock Up 25.5%

Shares of LUNG opened at $2.02 on Friday. The stock has a market capitalization of $83.33 million, a price-to-earnings ratio of -1.52 and a beta of 0.07. Pulmonx Corporation has a 1 year low of $1.31 and a 1 year high of $8.12. The business’s 50 day simple moving average is $1.75 and its 200-day simple moving average is $1.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%.The firm had revenue of $22.60 million during the quarter, compared to the consensus estimate of $21.73 million. As a group, equities analysts expect that Pulmonx Corporation will post -1.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on LUNG. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a research report on Thursday. Finally, Canaccord Genuity Group reduced their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.38.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC purchased a new position in Pulmonx during the 4th quarter valued at $27,000. FNY Investment Advisers LLC purchased a new stake in Pulmonx in the third quarter worth $29,000. Opal Capital LLC purchased a new stake in Pulmonx in the fourth quarter worth $29,000. Regatta Capital Group LLC bought a new stake in shares of Pulmonx during the fourth quarter worth $30,000. Finally, Jain Global LLC bought a new stake in shares of Pulmonx during the third quarter worth $30,000. 91.04% of the stock is owned by institutional investors.

Key Headlines Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.